RecruitingNCT06075433

Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure

A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of 1 Year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-Risk Procedure

Sponsor

Genoss Co., Ltd.

Enrollment

1,000 participants

Start Date

May 13, 2022

Study Type

OBSERVATIONAL

Conditions

Coronary Artery Disease Percutaneous Coronary Intervention Dual Antiplatelet Therapy

Summary

The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.

Eligibility

Min Age: 19 Years

Inclusion Criteria3

Patients of 19 and over
Patients with coronary artery disease treated with GENOSS SES
Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants

Exclusion Criteria5

Patients with cardiogenic shock at the time of hospitalization
Patients who are pregnant or planning to become pregnant
Patients with a life expectancy of less than 1 year
Patients participating in randomized controlled trials using other medical devices
Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration (However, other stent insertions are allowed due to failure of GENOSS DES insertion)

Interested in this trial?

Get notified about updates and connect with the research team.